HS-27

Research use only, not for human use.

HS-27 is a fluorescently-tethered inhibitor of Hsp90 with SNX-5422 tethered via a PEG linker to a fluorescein isothiocyanate or FITC. HS-27 can be used in see-and-treat paradigms.

HS-27, a fluorescently-tethered Hsp90 inhibitor, assays surface Hsp90 expression on intact tissue specimens. HS-27 is made up of the core elements of SNX-5422, an Hsp90 inhibitor, tethered via a PEG linker to a fluorescein derivative (fluorescein isothiocyanate or FITC), that binds to ectopically expressed Hsp90. HS-27 has potential use in a see-and-treat paradigm in breast cancer.

HS-27 labels all receptor subtypes of breast cancer, but not normal cells, and specifically binds to Hsp90 expressed on the surface of breast cancer cells before being internalized. HS-27 fluorescence is greater in tumor than non-tumor tissue.

——

——

Cytoskeleton/Cell Adhesion Molecules

HSP

HSP

——

——

1562024-11-6

993.13

C52H60N6O12S

>98% (HPLC)

In Vitro:?DMSO : 100 mg/mL (100.69 mM; Ultrasonic )

Cc1nn(c2CC(C)(C)CC(=O)c12)-c1ccc(C(N)=O)c(NCCCOCCOCCOCCOCCOCCCNC(=S)Nc2ccc3c(c2)C(=O)OC32c3ccc(O)cc3Oc3cc(O)ccc23)c1

——

(-20℃)

With Ice Pack

≥ 2 years